Mostafa Yazdimamaghani
Mostafa Yazdimamaghani
aLineberger Comprehensive Cancer Center, University of North
Carolina at Chapel Hill, Chapel Hill, NC, USA
bCenter for Nanotechnology in Drug Delivery and Division of
Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy,
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
a,b,
Oleg V Kolupaev
Oleg V Kolupaev
aLineberger Comprehensive Cancer Center, University of North
Carolina at Chapel Hill, Chapel Hill, NC, USA
cDuke Eye Center, Duke University, Durham, NC, USA
a,c,
Chaemin Lim
Chaemin Lim
bCenter for Nanotechnology in Drug Delivery and Division of
Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy,
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
dCollege of Pharmacy, CHA University, Seongnam-si,
Gyeonggi-do, Republic of Korea
b,d,
Duhyeong Hwang
Duhyeong Hwang
bCenter for Nanotechnology in Drug Delivery and Division of
Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy,
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
eCollege of Pharmacy, Keimyung University, Daegu, Republic
of Korea
b,e,
Sonia J Laurie
Sonia J Laurie
aLineberger Comprehensive Cancer Center, University of North
Carolina at Chapel Hill, Chapel Hill, NC, USA
a,
Charles M Perou
Charles M Perou
aLineberger Comprehensive Cancer Center, University of North
Carolina at Chapel Hill, Chapel Hill, NC, USA
a,
Alexander V Kabanov
Alexander V Kabanov
aLineberger Comprehensive Cancer Center, University of North
Carolina at Chapel Hill, Chapel Hill, NC, USA
bCenter for Nanotechnology in Drug Delivery and Division of
Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy,
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
a,b,
Jonathan S Serody
Jonathan S Serody
aLineberger Comprehensive Cancer Center, University of North
Carolina at Chapel Hill, Chapel Hill, NC, USA
fDepartment of Medicine, University of North Carolina School
of Medicine, Chapel Hill, NC, USA
gDepartment of Microbiology and Immunology, University of
North Carolina, Chapel Hill, NC, USA
a,f,g,*
aLineberger Comprehensive Cancer Center, University of North
Carolina at Chapel Hill, Chapel Hill, NC, USA
bCenter for Nanotechnology in Drug Delivery and Division of
Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy,
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
cDuke Eye Center, Duke University, Durham, NC, USA
dCollege of Pharmacy, CHA University, Seongnam-si,
Gyeonggi-do, Republic of Korea
eCollege of Pharmacy, Keimyung University, Daegu, Republic
of Korea
fDepartment of Medicine, University of North Carolina School
of Medicine, Chapel Hill, NC, USA
gDepartment of Microbiology and Immunology, University of
North Carolina, Chapel Hill, NC, USA
*Corresponding author. Lineberger Comprehensive
Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC,
USA. Jonathan_serody@med.unc.edu (J.S. Serody).
